The cycle moves the symptoms — and the medication stops working as well
Gabriela Kennedy, Megan Baran-Goldwax and Sarah Lippé at the University of Montreal published a scoping review in Women’s Health in June 2026 mapping what is known about the relationship between menstrual health and ADHD symptoms. Their search returned 691 records and, after screening, 20 studies met the criteria — participants aged 13 to 49, most studies published after 2020, the field young enough that the review is the first of its kind. The headline is simple and, for a great many people, will be self-evidently true the moment they read it: ADHD symptoms are not static across the month. They shift with the menstrual cycle.
The most consistent finding concerns the luteal phase — the days preceding menstruation, when estrogen drops. Multiple studies reported worsening of core ADHD symptoms during this window, with inattention emerging repeatedly across studies of differing design and population. A qualitative study of people with ADHD found participants describing reliably worse concentration, organisation, and forgetfulness during the mid-luteal phase and menstruation. The theoretical work the review draws on proposes a mechanism: estradiol supports dopamine signalling in the prefrontal circuits that handle executive control, so when estrogen falls sharply in the late luteal phase, those circuits lose some of their support, and the symptoms intensify.
The finding with the sharpest clinical edge is what happens to medication. Several studies reported that stimulant medication felt less effective during the luteal phase — that the dose carrying someone through the first three weeks of their cycle stopped doing the same work in the final week. This is not a minor inconvenience. It means a person can be correctly diagnosed, correctly medicated, and adherent to their prescription, and still spend a quarter of every month under-treated by a system that has no model for why. The review notes early case-series work in which clinicians raised stimulant doses specifically during the premenstrual phase and patients reported steadier symptoms across the cycle — but this evidence is preliminary and thinly powered. The point stands regardless of the fix: the standard fixed-dose model treats ADHD as a stable target in a population for whom, hormonally, it is not.
The review is careful about its own limits, and so is this piece. Twenty studies is a small literature, the methods are heterogeneous, sample sizes run from a single case to a few hundred, and several themes rest on case reports the authors rate “Unsatisfactory.” Directionality and causal mechanisms are mostly not established. What the review demonstrates is not a settled mechanism but a settled fact of experience finally reaching the literature: the cycle moves the symptoms, and the people living it have known for far longer than the research has.
Painful periods, heavy bleeding, and the iron the brain runs on
Beyond cycle phase, the review maps associations between specific menstrual health features and ADHD symptoms, and some of the numbers are striking. One study of adults found a 95% comorbidity rate between ADHD symptom severity and dysmenorrhea — severe menstrual pain. Studies of premenstrual dysphoric disorder, the most methodologically robust cluster in the review, consistently linked PMDD with heightened inattention, and one found that more than a quarter of the PMDD group also carried an ADHD diagnosis. Polycystic ovary syndrome, characterised by excess androgens, was linked specifically to impulsivity rather than inattention — a different menstrual condition mapping onto a different ADHD profile.
The mechanism that best repays attention is the one running through iron. Heavy menstrual bleeding — menorrhagia — is a primary cause of iron deficiency. One study in the review found that people with ADHD symptoms were more likely to report both heavy bleeding and iron-deficiency symptoms. The pathway the authors trace is specific and biologically clean: iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine. Low iron means constrained dopamine production. Dopamine is the neurotransmitter system most implicated in ADHD. So a heavy period, month after month, can lower the iron stores the brain needs to make the very neurotransmitter whose dysregulation defines the condition.
Read structurally, this is not a story about menstruation complicating ADHD. It is a story about how much of what gets labelled and treated as a fixed neurodevelopmental disorder is in fact a body meeting a fluctuating physiological environment that no one thought to measure. The iron pathway is the clearest case: the same person’s attentional capacity can vary across the month as a function of their blood iron, which varies as a function of their menstrual bleeding, none of which appears anywhere in a standard ADHD assessment. The assessment captures a snapshot and calls it a trait. The body underneath it is moving on a monthly tide the assessment cannot see.
This connects to an argument I’ve made across other domains — that the diagnostic apparatus catches a surface and treats it as a stable internal property of the person, while the conditions actually producing the variation go unmeasured because the apparatus has no category for them. Here the unmeasured variable is reproductive physiology, and the population whose physiology it is happens to be the population the apparatus was never built around in the first place.
Why this is only being studied now
The obvious question the review raises and then answers is: why is this only being mapped in 2026? The cycle is not new. The hormones are not new. The lived experience the qualitative studies record is not new. What is new is anyone in the research apparatus treating it as worth studying — and the reason it took this long is the same reason it was needed.
ADHD was built, as a diagnostic category, around the presentation that was easiest to see in boys: hyperactivity and externalising behaviour, the child disrupting the classroom. People assigned female at birth more often present with inattention — the internalising, quiet, drifting profile that disrupts nobody and gets noticed by no one. The consequence is measurable in the diagnosis ratios. In childhood, boys are diagnosed roughly four times as often as girls. By adulthood, when people seek their own assessments, the ratio equalises to one to one. That equalisation is the evidence: the childhood gap was never a difference in prevalence. It was a difference in who the apparatus was built to recognise.
The review’s authors name the mechanism directly, and it is the architectural core of the piece. The underrepresentation of female-typical ADHD presentations perpetuates a mischaracterisation of the disorder in people assigned female at birth, which contributes to their underdiagnosis, which misrepresents the true prevalence, which reinforces the assumption that they are less affected, and therefore need not be equally represented in research. The cycle sustains itself: limited representation leads to mischaracterisation, which leads to further exclusion, which renews the limited representation. Menstrual health and ADHD went unstudied for so long not as an oversight but as a structural output of a diagnostic category that was calibrated to a male default and then treated that calibration as the nature of the disorder. The research gap is not separate from the underdiagnosis. It is the same machine, viewed from a different year.
This is the demand-structure argument in a form that needs no extension. The substrate — the ADHD profile — was always present in AFAB people at the same rate. What varied was whether the apparatus was built to catch it. The whole history of female ADHD is a worked example of the corpus’s central claim: that what gets called a difference in prevalence is very often a difference in recognition, and the recognition is calibrated to whoever the system was designed around.
The erasure reproduces itself
The sharpest detail in the review is the one that turns the critique on the corrective literature itself. Of the 20 studies mapping menstrual health and ADHD — studies that exist specifically to address the historical neglect of AFAB experience — only two reported the gender identity of their participants. The rest referred to participants as “women” without distinguishing sex assigned at birth from gender identity, and without accounting for the transgender and gender-diverse people who menstruate, who have ADHD at elevated rates, and who have been even more thoroughly excluded from neurodevelopmental research than cisgender women.
So the literature built to correct one erasure reproduces the next one inside itself. The studies widen the lens enough to see people who menstruate, having spent decades not seeing them, and in the same motion collapse “people who menstruate” back into “women,” erasing the gender-diverse population at the precise moment of trying to be inclusive. The apparatus does not fail once and then correct. It fails, corrects at one level, and reproduces the same structural move at the next level down.
This is what makes the menstrual-health-and-ADHD literature worth watching as more than a clinical development. It is a live demonstration of how recognition works in this field — never complete, always calibrated to whoever the current frame was built around, always leaving a further population outside the lens. The cycle phase moves the symptoms; the iron moves the dopamine; the diagnostic history moved the research gap into being; and now the corrective research moves the erasure one step further along rather than ending it. The honest conclusion is not that the field has finally got it right. It is that the same structural pattern keeps operating, and the only question is who is currently outside the frame.
For the millions of people whose ADHD genuinely worsens every luteal phase, whose medication genuinely stops working in the final week of their cycle, whose attention genuinely tracks their blood iron, the practical implication is immediate and overdue: their experience is real, it is physiological, and the reason their clinicians have no model for it is historical rather than biological. The cycle was always moving the symptoms. The research is only now turning to look — and it is worth being honest, as the field turns, about how much it is still not seeing.
Citations
Kennedy, G., Baran-Goldwax, M. & Lippé, S. (2026) — Menstrual health and Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms: A scoping review — Women’s Health
Eng, A. G., Nirjar, U., Elkins, A. R. et al. (2024) — Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidence — Hormones and Behavior
Lockinger, K. & Gagnon, M. M. (2023) — Dysmenorrhea and psychological wellbeing among females with attention deficit hyperactivity disorder — Journal of Health Psychology
MacLean, B., Buissink, P., Louw, V. et al. (2025) — Women with Symptoms Suggestive of ADHD Are More Likely to Report Symptoms of Iron Deficiency and Heavy Menstrual Bleeding — Nutrients
Martin, J. (2024) — Why are females less likely to be diagnosed with ADHD in childhood than males? — The Lancet Psychiatry
